Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
 Full text 
Tuesday, 4 April 2017 - Strasbourg Revised edition

Medical devices - In vitro diagnostic medical devices (debate)

  Julie Girling (ECR). – Mr President, can I give my congratulations and thanks to both of the rapporteurs and all of the teams. I have to say I admire your stamina. You are an example to us all. And so here we are at last.

Patient safety is of paramount importance and ensuring that this should always be so is our top priority. I am often one of the first to say that additional regulation can be burdensome, however when it comes to the realm of public health, especially when lives are in jeopardy and the safety of our healthcare system is questioned, tighter oversight and control mechanisms are vital. Indeed, in the wake of the breast implant and metal—on—metal hip scandals of 2012, it is now more important than ever that patient confidence be restored.

I firmly believe that support for these proposals is warranted. With the introduction of more systematic post-market checks, as well as stricter monitoring and traceability measures, these proposals create a framework whereby errors are more easily identifiable, allowing for more targeted and efficient responses and minimising any negative fallout.

While focusing on consumer safety, I would also acknowledge the importance of innovation, and these proposals do exactly that. So I think you have got the balance right, and I will be very happy to vote for this tomorrow.

Legal notice - Privacy policy